Bristol-Myers Squibb and Bavarian Nordic have entered an agreement that provides BMS an exclusive option to license and commercialize PROSTVAC, Bavarian Nordic’s Phase III prostate-specific antigen (PSA)-targeting cancer immunotherapy in development for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).   Bavarian Nordic will receive an upfront payment of $60 million and would be entitled to $80 million should BMS exercise its option, plus additi...